Preclinical CRO (Target Discovery, Preclinical Optimization, IND-Enabling Safety) Market Trends And Growth Forecasts 2025-2026 & 2033 By Service, Development Stage, Indication, Model, End Use, Region

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the global preclinical CRO market include increased outsourcing by biopharma companies to reduce costs and access expertise, especially in developing markets like India and China with GLP-compliant facilities. Demand is driven by personalized medicine, advanced therapeutics, and strategic collaborations.

Dublin, May 26, 2026 (GLOBE NEWSWIRE) -- The "Preclinical CRO Market Size, Share & Trends Analysis Report by Service, Development Stage, Indication, Model, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets's offering.

The global preclinical CRO market size is anticipated to surge from USD 6.7 billion in 2025 to USD 12.8 billion by 2033, advancing at a CAGR of 8.4% between 2026 and 2033.

This growth is propelled by trends in economic outsourcing, regulatory requirements, and increasing scientific intricacies that solidify preclinical CROs as essential in early-stage drug development. The escalation in demand for toxicology, pharmacology, and efficacy studies further fuels this trend.

Biotech and biopharma companies increasingly outsource preclinical research to mitigate infrastructure costs and tap into specialized expertise, driving this market segment. The rising complexity of drug development processes, enhanced biopharma R&D investments, and stringent Good Laboratory Practice (GLP)-compliant study demands are pivotal in influencing market dynamics. Alongside, growing R&D offshoring trends, personalized medicine demand, and advanced therapeutic development are vital factors accelerating preclinical CRO market expansion.

The outsourcing inclination, especially evident in smaller and midsized biopharma entities lacking internal capacities, enables leveraging skillful resources and advanced infrastructure in cost-efficient locations. Emerging markets like India and China, distinguished by GLP-compliant facilities and competitive cost advantages, have become central to this trend. The integration of hybrid R&D strategies, combining onshore strategy with offshore execution, further amplifies this growth trend.

Moreover, strategic partnerships and initiatives by key players are enhancing outsourcing growth. In February 2026, Syngene International collaborated with Johns Hopkins University, harnessing joint capabilities for advancing early-stage research. Similarly, January 2026 witnessed an extended collaboration between Syngene International and Bristol Myers Squibb through 2035, emphasizing discovery and preclinical capabilities. These initiatives are poised to advance market growth significantly.

The demand for personalized medicine and advanced therapeutics is simultaneously prompting the preclinical CRO industry's growth. In March 2026, NJ Bio and Ajinomoto Bio-Pharma Services formed a partnership to enhance the ADC development process, integrating the AJICAP technology for improved stability and pharmacokinetics. Furthermore, an agreement between Eli Lilly and Insilico Medicine, valued up to USD 2.75 billion, aims to utilize AI to expedite drug discovery and development.

Report Highlights:

• Detailed Market Analysis: Understand regional and segment-specific market dynamics.
• Competitive Landscape: Investigate the positions of major market players.
• Future Trends Insights: Discover drivers shaping market future.
• Actionable Insights: Leverage insights to strategize and uncover new opportunities.

Key Attributes:

Report Attribute	Details
No. of Pages	120
Forecast Period	2025 - 2033
Estimated Market Value (USD) in 2025	$6.7 Billion
Forecasted Market Value (USD) by 2033	$12.8 Billion
Compound Annual Growth Rate	8.4%
Regions Covered	Global

Companies Featured

• Eurofins Scientific
• ICON plc
• WuXi AppTec
• Medpace Holdings, Inc.
• Charles River Laboratories
• PPD (Thermo Fisher Scientific, Inc.)
• SGS SA (SGS Societe Generale de Surveillance SA.)
• Intertek Group plc (IGP)
• Labcorp
• Crown Bioscience
• Scantox

Global Preclinical CRO Market Segmentation

Service Outlook (Revenue, USD Million, 2021-2033):

• Bioanalysis and DMPK Studies, In vitro ADME, Toxicology Testing, GLP, Non-GLP, and more

Development Stage Outlook:

• Target Discovery, Preclinical Optimization, IND-Enabling Safety

Indication Outlook:

• Oncology, CNS, Infectious Diseases, Cardiovascular Diseases, and others

Model Outlook:

• In Vitro, In Vivo, Ex Vivo

Regional Outlook:

• North America, Europe, Asia Pacific, Latin America, Middle East & Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Preclinical CRO Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN26052026004107003653ID1111169277